Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
Two brothers Same Diagnosis – 6 Months to Live.
Learn a remarkable terminal cancer survival story of two brothers facing the same dire diagnosis and the journey to beat the odds.
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
Two brothers Same Diagnosis – 6 Months to Live.
Learn a remarkable terminal cancer survival story of two brothers facing the same dire diagnosis and the journey to beat the odds.
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
